These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30596408)

  • 21. Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation.
    Wilkinson JB; Shah C; Amin M; Nadeau L; Shaitelman SF; Chen PY; Grills IS; Martinez AA; Mitchell CK; Wallace MF; Vicini FA
    Clin Breast Cancer; 2017 Feb; 17(1):55-60. PubMed ID: 27666436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
    Zhang T; Li Q; Xu B; Zhang P; Yuan P; Ma F; Wang J; Fan Y
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited overall survival in patients with brain metastases from triple negative breast cancer.
    Morris PG; Murphy CG; Mallam D; Accordino M; Patil S; Howard J; Omuro A; Beal K; Seidman AD; Hudis CA; Fornier MN
    Breast J; 2012; 18(4):345-50. PubMed ID: 22607041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
    Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
    J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
    Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
    Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.
    Niwińska A; Murawska M; Pogoda K
    Cancer; 2010 Sep; 116(18):4238-47. PubMed ID: 20549816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
    Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
    Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry.
    Laakmann E; Witzel I; Scriba V; Grzyska U; Zu Eulenburg C; Burchardi N; Hesse T; Würschmidt F; Fehm T; Möbus V; von Minckwitz G; Loibl S; Park-Simon TW; Mueller V
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
    Sperduto PW; Kased N; Roberge D; Chao ST; Shanley R; Luo X; Sneed PK; Suh J; Weil RJ; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
    J Neurooncol; 2013 May; 112(3):467-72. PubMed ID: 23462853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
    Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.